4.8 Article

Targeted capture and massively parallel sequencing of 12 human exomes

Journal

NATURE
Volume 461, Issue 7261, Pages 272-U153

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nature08250

Keywords

-

Funding

  1. National Institutes of Health/National Heart Lung and Blood Institute
  2. National Institutes of Health/National Human Genome Research Institute
  3. National Institutes of Health/National Institute of Child Health and Human Development
  4. Washington Research Foundation
  5. Agency for Science, Technology and Research, Singapore
  6. Howard Hughes Medical Institute

Ask authors/readers for more resources

Genome-wide association studies suggest that common genetic variants explain only a modest fraction of heritable risk for common diseases, raising the question of whether rare variants account for a significant fraction of unexplained heritability(1,2). Although DNA sequencing costs have fallen markedly(3), they remain far from what is necessary for rare and novel variants to be routinely identified at a genome-wide scale in large cohorts. We have therefore sought to develop second-generation methods for targeted sequencing of all protein-coding regions ('exomes'), to reduce costs while enriching for discovery of highly penetrant variants. Here we report on the targeted capture and massively parallel sequencing of the exomes of 12 humans. These include eight HapMap individuals representing three populations(4), and four unrelated individuals with a rare dominantly inherited disorder, Freeman-Sheldon syndrome (FSS)(5). We demonstrate the sensitive and specific identification of rare and common variants in over 300 megabases of coding sequence. Using FSS as a proof-of-concept, we show that candidate genes for Mendelian disorders can be identified by exome sequencing of a small number of unrelated, affected individuals. This strategy may be extendable to diseases with more complex genetics through larger sample sizes and appropriate weighting of non-synonymous variants by predicted functional impact.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available